Skip to content
The Policy VaultThe Policy Vault

Dupixent (dupilumab) — Highmark

Bullous Pemphigoid

Initial criteria

  • age ≥ 18 years
  • Diagnosis of bullous pemphigoid confirmed by dermatologist, allergist, or immunologist
  • Therapeutic failure, contraindication, or intolerance to one of the following: high potency to super high potency topical corticosteroids OR oral corticosteroids

Reauthorization criteria

  • Member has experienced disease control (e.g., no new lesions and existing lesions are beginning to heal) OR reduction in number of relapses OR improvement in BP symptoms OR reduction in oral corticosteroid use